| Literature DB >> 26305564 |
Zhixin Xu1, Lei Gan1, Tongyu Li1, Chang Xu1, Ke Chen1, Xiaodan Wang1, Jian G Qin2, Liqiao Chen1, Erchao Li1.
Abstract
Nile tilapia Oreochromis niloticus is a freshwater fish but can tolerate a wide range of salinities. The mechanism of salinity adaptation at the molecular level was studied using RNA-Seq to explore the molecular pathways in fish exposed to 0, 8, or 16 (practical salinity unit, psu). Based on the change of gene expressions, the differential genes unions from freshwater to saline water were classified into three categories. In the constant change category (1), steroid biosynthesis, steroid hormone biosynthesis, fat digestion and absorption, complement and coagulation cascades were significantly affected by salinity indicating the pivotal roles of sterol-related pathways in response to salinity stress. In the change-then-stable category (2), ribosomes, oxidative phosphorylation, signaling pathways for peroxisome proliferator activated receptors, and fat digestion and absorption changed significantly with increasing salinity, showing sensitivity to salinity variation in the environment and a responding threshold to salinity change. In the stable-then-change category (3), protein export, protein processing in endoplasmic reticulum, tight junction, thyroid hormone synthesis, antigen processing and presentation, glycolysis/gluconeogenesis and glycosaminoglycan biosynthesis-keratan sulfate were the significantly changed pathways, suggesting that these pathways were less sensitive to salinity variation. This study reveals fundamental mechanism of the molecular response to salinity adaptation in O. niloticus, and provides a general guidance to understand saline acclimation in O. niloticus.Entities:
Mesh:
Year: 2015 PMID: 26305564 PMCID: PMC4548949 DOI: 10.1371/journal.pone.0136506
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Summary statistics of the RNA-seq data.
| Sample Name | 0‰ | 8‰ | 16‰ | Total | Average |
|---|---|---|---|---|---|
| Total reads (×106) | 25.3 | 27.7 | 30.7 | 83.7 | 27.9 |
| Total reads after (×106) | 22.9 | 22.6 | 25.1 | 70.6 | 23.5 |
| Reads filter (%) | 90.6 | 81.7 | 81.8 | 84.3 | 84.2 |
| Mapped reads (×106) | 19.6 | 18.8 | 20.9 | 59.3 | 19.7 |
| Mapping rate (%) | 85.5 | 83.0 | 83.5 | 84.0 | 83.8 |
| Unique mapping (×106) | 19.2 | 18.4 | 20.6 | 58.2 | 19.4 |
| Unique mapping rate (%) | 83.9 | 81.5 | 82.0 | 82.4 | 82.6 |
Fig 1Eight types of gene change tendencies signed with gene numbers.
(A): Numbers cited at the upper left corner represent each tendency. Figures cited at the lower left corner represent the number of genes in the tendency. (B): Numbers cited at the upper left corner represent each tendency. Numbers marked at the lower left corner represent the P-value of each tendency type. The colors represent significantly different levels.
GO terms and GO pathways (P<0.05) with all differently expressed genes.
| Tendency | 0 | 1 | 3 | 4 | 6 | 7 |
| GO terms | 229 | 210 | 145 | 265 | 122 | 152 |
| Different genes | 107 | 453 | 51 | 324 | 139 | 132 |
| KEGG pathways | 7 | 19 | 4 | 26 | 10 | 10 |
| Different genes | 46 | 213 | 18 | 161 | 44 | 59 |
Pathways contained in the constant change category.
| Tendency | Pathways | P-value | Differentially expressed genes |
|---|---|---|---|
| 0 | Fat digestion and absorption | 6.06E-03 | APOA1, DGAT2, MOGAT2 |
| Retinol metabolism | 1.78E-02 | UGT2A1, DGAT2, DHRS13 | |
| Vitamin digestion and absorption | 2.88E-02 | RBP2, APOA1 | |
| Alzheimer's disease | 2.72E-03 | LRP1,MAPT,NDUFA4,CAPN2, CASP7, NDUFA7 | |
| Parkinson's disease | 1.51E-02 | SLC6A3, VDAC3, NDUFA4, NDUFA7 | |
| Chemical carcinogenesis | 1.74E-02 | UGT2A1, CBR1, GSTT3 | |
| Metabolism of xenobiotics by cytochrome P450 | 1.70E-02 | GSTT3, UGT2A1, CBR1 | |
| 7 | Steroid hormone biosynthesis | 2.69E-03 | UGT2A1,SULT3A1, SULT2B1, HSD17B7 |
| Steroid biosynthesis | 2.35E-06 | HSD17B7, LSS, SQLE, FDFT1, DHCR24 | |
| Ovarian steroidogenesis | 3.21E-02 | CYP2J6, ADCY8, HSD17B7 | |
| Sulfur metabolism | 1.55E-02 | SULT3A1, SULT2B1 | |
| Arginine and proline metabolism | 1.73E-02 | OTC, ODC1, SAT1 | |
| Protein digestion and absorption | 3.50E-02 | COL5A1, COL11A1,COL17A1, SLC7A9 | |
| Porphyrin and chlorophyll metabolism | 4.92E-02 | UGT2A1, CP | |
| Complement and coagulation cascades | 1.01E-02 | C6, C3, PLG, SERPINF2 |
Pathways contained in the stable-then-change category.
| Tendency | Pathways | P-value | Differentially expressed genes |
|---|---|---|---|
| 3 | Retinol metabolism | 2.09E-02 | BCMO1,UGT1A5 |
| Folate biosynthesis | 4.11E-02 | ALPL | |
| Other types of O-glycan biosynthesis | 1.02E-02 | B4GALT1, UGT1A5 | |
| Glycosaminoglycan biosynthesis—keratan sulfate | 2.39E-03 | B3GNT7, B4GALT1 | |
| 4 | Biosynthesis of unsaturated fatty acids | 3.18E-02 | ACOT7, ACOT1, ACOT3 |
| Metabolic pathways | 4.55E-02 | CYP3A25,ALOX5,ACSS1,CYP3A1,PRODH,LPIN1,GAL3ST1,TPI1, CKM,CBR1,PKM,CYP17A1,NME2,POLR2H,PGAM2,AK5,CKMT2,GFPT2,CKM,DHODH,PCYT1B,LAO1, PCK1,LDHA,NDUFV1,PTGDS, PISD,ALDOA,IMPA1,GLS,GADL1, PIGV,XYLT1,IDH2,GADL1,AMPD, HK1, PHOSPHO1 | |
| Thyroid hormone synthesis | 1.40E-05 | HSPA5,HSPA5,HSPA5,PDIA4, HSPA5,HSPA5,HSPA5,HSP90B1, ATP1A3,HSPA5,HSPA5 | |
| Ovarian steroidogenesis | 3.96E-02 | ACOT3,ALOX5, CYP17A1, ACOT1, IGF1R | |
| Protein processing in endoplasmic reticulum | 4.99E-07 | HSPA5, PDIA4, CALR, HSPA5, HSPA5, HSPA5, HSP90B1, HSPA5, PDIA6, HSPA5, HYOU1, DNAJB11, HSPA5, SEC31A, DERL1, CALR, HSPA5, CALR, SSR1 | |
| Arginine and proline metabolism | 1.64E-02 | CKM, GLS, PRODH, CKM, CKMT2 | |
| Protein export | 2.30E-07 | HSPA5, HSPA5, HSPA5, HSPA5, HSPA5, HSPA5, HSPA5, HSPA5 | |
| Biosynthesis of amino acids | 3.23E-02 | PGAM2, ALDOA, IDH2, TPI1, PKM | |
| Glycolysis/gluconeogenesis | 1.89E-04 | PKM, PGAM2, PCK1, LDHA, ALDOA, HK1, ACSS1, TPI1 | |
| Carbon metabolism | 1.57E-02 | TPI1, PKM, PGAM2, ALDOA, IDH2, HK1, ACSS1 | |
| Proximal tubule bicarbonate reclamation | 1.59E-02 | SLC9A3, PCK1, GLS, ATP1A3 | |
| Pyruvate metabolism | 2.10E-02 | ACSS1, PKM, PCK1, LDHA | |
| Chemical carcinogenesis | 3.96E-02 | GSTM5, CYP3A25, CYP3A13, CBR1, GSTO1 | |
| Metabolism of xenobiotics by cytochrome P450 | 3.83E-02 | GSTO1, GSTM5, CYP3A25, CYP3A13, CBR1 | |
| p53 signaling pathway | 3.12E-02 | GADD45G,VAT1L,IGFBP3,GADD45B,ZMAT3 | |
| PI3K-Akt signaling pathway | 3.39E-02 | DDIT4,VAT1L, IGFBP3, GADD45B, ZMAT3 | |
| Cardiac muscle contraction | 3.00E-03 | MYH6,RYR1,MYH7,ATP2A1,MYH6, TPM1, TNNC2, ACTC1, ATP1A3 | |
| Dilated cardiomyopathy | 5.50E-04 | ACTC1, MYH6, RYR1, MYH7, TTN, TITIN, ATP2A1, MYH6, TPM1, TNNC2, ACTB, SGCG | |
| Hypertrophic cardiomyopathy (HCM) | 2.97E-04 | ACTB, SGCG, ACTC1, MYH6, RYR1, MYH7, TTN, TITIN, ATP2A1, MYH6, TPM1, TNNC2 | |
| Prion disease | 8.71E-07 | HSPA5,HSPA5,HSPA5,HSPA5,C7,HSPA5,EGR1,HSPA5,HSPA5,HSPA5 | |
| Viral myocarditis | 9.13E-07 | MYH4,MYH4,ACTB,SGCG,MYH6,MYH4, MYH13, MYH7, MYH2, MYH1, EIF4G3, MYH2, MYH4, MYH6, MYH4, MYH4, MYH4 | |
| Antigen processing and presentation | 2.65E-05 | CALR, HSPA5, HSPA5, HSPA5, HSPA5, HSPA5, HSPA5, CALR, HSPA5, CALR, HSPA5 | |
| Chagas disease | 3.32E-02 | CALR, GNA14, CALR, IRAK1, JUN, CALR, TLR13 | |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 4.57E-02 | ACTB,SGCG,RYR1,ACTN3,ATP2A1,DSG2 | |
| HIF-1 signaling pathway | 2.08E-02 | EGLN3, IGF1R, LDHA, CAMK2D, EPO, ALDOA, HK1 | |
| Tight junction | 1.37E-06 | MYH6, CLDN4, MYH4, MYH13, MYH7, ACTN3, MYH2, MYH1, MYH2, MYLPF, MYH4, MYH6, MYH4, MYH4, MYH4, MYH4, MYH4, ACTB, CLDN4, MYLPF |
Fig 2Gene act subnetworks in the 0 vs 16 psu categories.
(A): complement and coagulation cascades; (B): cell connection; (C): endoplasmic reticulum activity; (D): fat digestion and absorption; (E): steroid biosynthesis; (F): glycolysis/gluconeogenesis; (G): signal transport. The red ball represents the up-regulated genes, while the green ball represents the down-regulated genes. The connections of genes were generated from the data analysis comprising GO analysis and KEGG pathway. The solid lines represent the relationships between genes. The dashed lines represent the genes that have an indirect effect. The arrow represents activation. The flathead represents suppression. ‘a’ represents activation; ‘b’ represents binding; and ‘c’ represents compound.
Fig 3Gene act subnetworks in the 0 vs 8 psu categories.
(A): glucose utilization; (B): nucleotide metabolism; (C): protein and amino acid metabolism; (D): cytoskeleton; (E): oxidative stress; (F): PI3K signaling pathways; (G): lipid and glycerophospholipid metabolism. The red ball represents the up-regulated genes, while the green ball represents the down-regulated genes. The connections of genes were generated from the data analysis consisting of GO analysis and KEGG pathway. The solid lines represent the relationships between genes. The dashed lines represent the genes that have an indirect effect. The arrow represents activation. The flathead represents suppression. ‘a’ represents activation; ‘b’ represents binding; and ‘c’ represents compound. The abbreviation ‘dep’ represents phosphorylation; ‘dis’ represents dissociation; and ‘inh’ represents inhibition.
Fig 4Gene act subnetworks in the 8 vs 16 psu categories.
(A): cytoskeleton; (B): PI3K signaling pathways; (C): endoplasmic reticulum activity; (D): lipid and glycerophospholipid metabolism; (E): carbohydrates and pyruvate metabolism; and (F): steroid hormone metabolism and oxidative stress. The red balls represent up-regulated genes, while the green balls represent down-regulated genes. The connections of genes were generated from the data analysis consist of GO analysis and KEGG pathway. The solid lines represent the relationships between the genes. The dashed lines represent the genes that have an indirect effect. The arrow represents activation. The flathead represents suppression. ‘a’ represents activation; ‘b’ represents binding; and ‘c’ represents compound. The abbreviation ‘dep’ represents phosphorylation; ‘dis’ represents dissociation; and ‘inh’ represents inhibition.
Fig 5Co-expression network of differentially expressed genes in freshwater and 16 psu.
The greater the value of k-core is, the more strongly the differentially expressed genes are co-expressed according to the size of the ball. The labels from one to eight represent the importance of genes. The red represents the most significant and the pink means the least significant.
Fig 6Validation of Q-PCR.
Comparison of the relative log2 (fold changes) between RNA-Seq and qPCR after salinity acclimation compared to the control, as normalized with the EF1A gene.
Fig 7Summary of the transcriptional changes of O. niloticus is shown under the salinity domestication.
The right-angle quadrilateral represents the pathways, and the rounded quadrilateral represents the important intermediates.
List of the genes validated by qPCR.
| Gene | Abbreviation | Primer sequence | Amplicon length |
|---|---|---|---|
| Sulfotransferase family cytosolic 2B member 1 | SULT2B1 | GGTCAGCACACTTCAGCGATGAT | 107 |
| GTCACTCTCATTCACTGGCATTGGA | |||
| Glyceraldehyde-3-phosphate dehydrogenase | GAPDHS | AAGAAGCATCATCCGTGAGGTTACT | 80 |
| TCCATTGATTCCAACACAGAGGTCT | |||
| Complement C3 | C3 | GCAGCACCTGGTTGACAGCATAT | 92 |
| GACGGCGTTACAGATCACTTCACTT | |||
| cyclin-B2 | CCNB2 | TCTGAGGTCGCTGCTGCTTC | 91 |
| CATAGGTAGAGTAGTGCTGCTGTGT | |||
| D(4) dopamine receptor | DRD4 | GGTTGCTTCTTGTTCTGTTGGACTC | 101 |
| GTGACAGTGCTCATTAGACCAGGAT | |||
| Small cytidine deaminase | CDA | GTGGAGAATGCGAGTTACAATCTGG | 118 |
| GGTCACTCTCGTCACTGGCAAT | |||
| fizzy-related protein homolog | FZR1 | ATGCCTCCGCTCCAGTCAGA | 111 |
| CTTGTTGTCATTGCCGCCAGAG | |||
| Glutathione S-transferase theta-1 | GSTT1 | TCGCTCAACCTGTTGGAGGAGAA | 94 |
| TCCACCACAGCCACCACATCT | |||
| microtubule-associated protein tau | MAPT | GCAACTCGCAGGAGCATCTTCA | 112 |
| CTTGGCGGTTATGGACGGTCTT | |||
| Phosphatidate cytidylyltransferase 2 | CDS2 | CAAGGAGGCTGATGGCGATGAC | 101 |
| TGGCGAGAGGATAATCTGGAGTGT | |||
| Alpha-2-antiplasmin | SERPINF2 | TCTGTTCTCTGGTCCTGACCTCTC | 101 |
| CGACGCCTTCTTCACTGAGTTCTAT | |||
| DNA replication licensing factor MCM3 | MCM3 | TGATTCAGAGGAGGAGGAGGAGATG | 104 |
| CATACGGGCTGTAGGGCTCACT | |||
| bile acid receptor | NR1H4 | GGAATGCTGGCTGAATGTCTGTTGA | 95 |
| CCTGCTGTCCGTGTTCTCCTCTT | |||
| histone-lysine N-methyltransferase, H3 lysine-79 specific | DOT1L | AGGAGGTGAATCGGACGCAGAA | 95 |
| ACGAAGAGGAAGACGAGGATGAAGA | |||
| complement component C6 | C6 | GGACTCGCAGCATGGACCTT | 100 |
| CAGCATCATCACGACTCACATTGG | |||
| cyclin-dependent kinase 2 | CDK2 | GGCTGGACCATAGAGTCATTGAGAA | 95 |
| CCACCTGCTGCCACCATCAT | |||
| sonic hedgehog protein A | SHH | GGCAAGATCGCACGCAATTCTGA | 108 |
| CGCCTGTGTTCTCCTCGTCCTT | |||
| Diacylglycerol O-acyltransferase 2 | DGAT2 | CTAGGAAGATGACTGGTTGCTGCTA | 91 |
| GTGCGATGACGAAGGTGGTGAA | |||
| 2-acylglycerol O-acyltransferase 2 | MOGAT2 | CTGCCACTTCACCATCTCTGTAACT | 120 |
| TCAGCCAGTAGCGAGTGAACATC | |||
| UDP-glucuronosyltransferase 2B17 | UGT2B17 | TCAGATTGCCCAGTATTTGCTACCA | 113 |
| CCACTCTCATTAGCCACAGGTCAG | |||
| cDNA, FLJ96434, highly similar to Homo sapiens cytochrome P450, family 2, subfamily J, polypeptide 2 (CYP2J2), mRNA | CYP2J2 | ACTTTGCTGGGACTGACACTACATC | 102 |
| GGTCTATCTCCTCCTGGCATTGTTC | |||
| ITGA10 protein | ITGA10 | GGCACCACCATATCCAGTCTTCCA | 95 |
| ACGGCACCTCTGTTATCATCCTCAA | |||
| 3-keto-steroid reductase | HSD17B7 | CCTTACACCGTACAATGGAGCAGAG | 108 |
| GTCCCAAGCCCTGATGTTAAACTGT | |||
| UDP-glucuronosyltransferase 2A1 | UGT2A1 | CACACCTTGTATAACGCAACTCAGT | 92 |
| GCTTCAAGTTCGCTATCACGGTTA | |||
| cDNA FLJ75329, highly similar to Homo sapiens LAG1 longevity assurance homolog 2 (S. cerevisiae), transcript variant 2, mRNA | CERS2 | CGGTTGATGACAATGATGAAGAGGA | 95 |
| GTTAGCCAGCGATGCCAGTCT | |||
| Patatin-like phospholipase domain containing 2 | PNPLA2 | GGCTGGACCATAGAGTCATTGAGAA | 95 |
| CCACCTGCTGCCACCATCAT | |||
| cDNA FLJ75392, highly similar to Homo sapiens hexokinase II (HKII) mRNA | HK2 | GGCGAGTCCAACATTCAGATAACCA | 107 |
| TACTTCTCCACCTTACCGAGCACAT |
Pathways contained in the change-then-stable category.
| Tendency | Pathways | P-value | Differentially expressed genes |
|---|---|---|---|
| 1 | Fat digestion and absorption | 7.04E-03 | PPARA,PPAP2A,FABP2, PLA2G12B, APOB, APOA1 |
| PPAR signaling pathway | 1.68E-04 | APOA1, FABP4, ACSL5, PPARA, APOA1, FABP6, ACSBG2, FABP2, FABP4, RXRG | |
| Ether lipid metabolism | 3.77E-02 | PPAP2A, PLD1, PLA2G12B, PLB1 | |
| Metabolic pathways | 1.73E-04 | NDUFS4, NDUFS5, PLB1, ALPL, CYP4F18, FUT9, GOT1, RFK, GGT5, LCT, POLE4, ASAH2, NDUFS1, COX6A1, NME3, CYP2R1, CYP27B1, COX5A, NDUFS6, ALPI, INPP5J, UCK2, NDUFB2, COX7C, GCDH, LCT, PGP, ATP6V1H, SAT2, GCH1, FASN, UQCRQ, LCMT2, NDUFA11, ACLY, ACSL5, NDUFB3, ACLY, COX6B1, NDUFA4, POLR2J, THTPA, PPAP2A, PLD1, UROD, ACSBG2, LIPASE, DBH, COX7B, ACACA, FBP2, ODC1, NT5C2, PHOSPHO1, LPIN1, GDA, URAH, COX6B1, LIAS, DCTD, GCK, PLA2G12B, DTYMK | |
| Fatty acid biosynthesis | 2.36E-02 | FASN, ACACA | |
| Ribosome | 4.42E-14 | RPS27L, RPS25, RPS15A, RPL28, RPS27A, RPS27RT, MRPS16, RPS12, RPS29, RPL26, RPS23, MRPS17, MRPS21, RPS27RT, RPL32, RPL35, RPS5, RPL13A, RPL37, RPL17, RPS10, RPL35A, RPL7A, RPS28, RPS19 | |
| Proteasome | 3.37E-02 | PSMB6, SHFM1, PSMB4, PSMB9 | |
| Vitamin digestion and absorption | 3.37E-02 | APOA1, APOA1, PLB1, APOB | |
| Folate biosynthesis | 1.38E-02 | ALPI, GCH1, ALPL | |
| Oxidative phosphorylation | 3.31E-07 | COX7A2, NDUFS1, COX6A1, COX5A, NDUFS6, NDUFB2, COX7C, ATP6V1H, UQCRQ, NDUFA11, NDUFB3, COX6B1, NDUFA4, COX7B, COX6B1, NDUFS4, NDUFS5 | |
| Alzheimer's disease | 8.00E-05 | NDUFS4, NDUFS5, ERN1, COX7A2, NDUFS1, COX6A1,COX5A,NDUFS6, NDUFB2, COX7C, APOA1, UQCRQ, NDUFA11, NDUFB3, COX6B1, NDUFA4, COX6B1, COX7B | |
| Parkinson's disease | 1.38E-05 | COX6B1,NDUFS4,NDUFS5,COX5A, COX7A2,NDUFS1,COX6A1,UQCRQ, NDUFS6,NDUFB2,COX7C, COX7B, NDUFA11, NDUFB3, COX6B1, NDUFA4 | |
| Non-alcoholic fatty liver disease (NAFLD) | 1.36E-06 | COX7B,COX6B1,NDUFS4,ERN1,NDUFS5,JUN, COX7A2, COX6A1, COX5A, NDUFS6, NDUFB2, COX7C, UQCRQ, NDUFA11, NDUFB3, COX6B1, NDUFA4, PPARA | |
| Huntington's disease | 1.85E-04 | COX6B1, NDUFA4, POLR2J, COX7B, COX6B1, NDUFS4, NDUFS5, COX7A2, NDUFS1, COX6A1, COX5A, NDUFS6, NDUFB2, COX7C, UQCRQ, NDUFA11, NDUFB3 | |
| Cardiac muscle contraction | 3.89E-06 | ACTC1, COX6B1, COX7B, COX6B1, TNNC2, COX7A2, COX6A1, COX5A, TPM1, COX7C, MYH6, ATP1B1, MYL4, ACTC1, TNNT2, UQCRQ | |
| Dilated cardiomyopathy | 4.86E-03 | TNNT2, ITGA6, ACTC1, TNNC2, IGHV9, DES, ITGB4, TPM1, ITGB3, MYH6, ITGA6, ACTC1 | |
| Hypertrophic cardiomyopathy (HCM) | 7.40E-03 | ITGA6, ACTC1, TNNT2, ITGA6, ACTC1, TNNC2, DES, ITGB4, TPM1, ITGB3, MYH6 | |
| Small cell lung cancer | 1.36E-02 | RXRG,FHIT, RXRG,FHIT, TRAF5, ITGA6, CDK4, CDK4, ITGA6, LAMC3, MYC | |
| Pyrimidine metabolism | 2.88E-02 | POLE4, NME3, UCK2, POLR2J, NT5C2, DCTD, DTYMK | |
| 6 | MicroRNAs in cancer | 2.39E-03 | CDKN1B, SOX12, CYP24A1, CD44, BMF, FSCN1 |
| Circadian rhythm—mammal | 2.85E-02 | PRKAG3 | |
| Rheumatoid arthritis | 3.20E-02 | ANGPT1, H2-EA-PS, H2-EB2 | |
| Asthma | 3.55E-02 | H2-EB2, H2-EA-PS | |
| Staphylococcus aureus infection | 2.67E-02 | H2-EA-PS, H2-EB2, ITGAX | |
| Cell cycle | 4.97E-02 | CDKN1B,STAG1,MCM6 | |
| Purine metabolism | 3.10E-02 | NT5C2, ENTPD2, PDE1B, PDE6D | |
| Hematopoietic cell lineage | 3.38E-02 | ITGAX, CD44, H2-EB2 | |
| Leishmaniasis | 3.85E-02 | ITGAX, H2-EA-PS, H2-EB2 | |
| ECM-receptor interaction | 3.85E-02 | COL6A6, CD44, ITGA11 |